C
The Cooper Companies, Inc.
COO · Healthcare
Q1 FY2026
Earning ended Jan 31, 2026Report generated Mar 15, 2026
Contact Lens Excellence Trapped Inside a Capital Allocation Problem
Most investors see a reliable medical consumables compounder with an exciting myopia management kicker — what they're missing is that the ROIC math has been quietly screaming for five years that CooperSurgical's acquisition strategy has consumed more value than CooperVision has created, and today's multiple assumes that equation reverses without requiring any proof. The atropine threat to MiSight is the second thing most models don't price: Cooper's entire re-rating thesis rests on a lens franchise that a single pharmaceutical approval could structurally impair.
Flowly Score
Apr 16 Close
-54%$69.38
Fair Value
$32.00
39
Below Averageat $69.38
Business Strength6/10
CooperVision is a genuinely excellent recurring-revenue business with real regulatory moats in MiSight and PARAGARD, but CooperSurgical's serial acquisition binge has systematically buried those returns in goodwill — a five-year ROIC averaging well below the cost of capital is the verdict, not a technicality. The jewel exists; management has just made it expensive to own.
Financial Resilience6/10
Cash conversion is clean and the Piotroski score reflects genuine earnings quality, but a net debt load north of two billion sitting on a business whose ROIC barely exceeds bond yields is a structural constraint, not a manageable nuisance. The pivot to buybacks and CapEx discipline is encouraging, but the balance sheet leaves little room for the next strategic mistake.
Growth & Trajectory6/10
MiSight's twenty-plus percent growth and the pediatric myopia epidemic in Asia are the real story here — a new clinical category, not incremental share gain — but organic growth decelerating to mid-single digits while Japan loses legacy hydrogel share to price competitors shows the business is running on two very different speeds. The second half recovery thesis is plausible but requires execution Cooper hasn't yet demonstrated consistently.
Valuation2/10at $69.92
A business averaging ROIC well below its cost of capital for five years is destroying intrinsic value with each incremental dollar deployed, and the current multiple prices in a rerate that requires flawless execution of the exact strategy that has underdelivered — even the optimistic DCF scenario implies substantial downside from today's price. There is no margin of safety here; you are paying for a future Cooper that doesn't yet exist.
Risk4/10
The single most dangerous risk is pharmacological: low-dose atropine drops are already being prescribed off-label for childhood myopia, and an FDA-approved topical therapy would render MiSight's hardware exclusivity irrelevant overnight with no recourse for Cooper. Stack PARAGARD mass tort litigation, fertility's exposure to US reproductive medicine politics, governance gaps, and a valuation that prices in optimism while leaving zero cushion for error, and the risk profile is materially worse than the stalwart label implies.
Cooper is the rare case where the business quality analysis and the valuation analysis point in genuinely opposite directions — the former is better than average, the latter is worse than almost any reasonable entry point. CooperVision sits on a real moat: regulatory exclusivity in myopia management, a global number-two scale position in precision lens manufacturing, and the kind of professional channel stickiness where optometrists build their workflows around your products and patients never think to switch. But that moat has been systematically monetized to fund CooperSurgical acquisitions at prices that require a decade of perfect integration to justify, and the ROIC history is the evidence that perfection hasn't arrived. The trajectory is genuinely bifurcated in a way the blended numbers obscure. MiSight is early in what could be a generational growth curve — the pediatric myopia epidemic in East Asia is not a marketing narrative, it is a demographic and public health fact, and Cooper holds the only FDA-approved contact lens solution. That franchise, isolated, is worth paying a meaningful premium for. CooperSurgical, meanwhile, is a patchwork built at cycle-peak prices that is now navigating fertility market softness, PARAGARD litigation, and political risk around reproductive medicine simultaneously. The strategic review process is the market's acknowledgment that the two businesses may be worth more apart than together. The single biggest risk is pharmaceutical substitution of MiSight's core value proposition. Atropine drops for myopia control are already in widespread off-label use; multiple pharma companies are pursuing formal approval pathways; and if a once-nightly drop becomes the standard of care, Cooper's hardware exclusivity becomes a legacy asset rather than a growth engine. Unlike a contact lens competitor, a pharmaceutical entrant wouldn't need to replicate Cooper's distribution relationships, manufacturing scale, or fitting expertise — they would simply route around all of it. That is the risk the current multiple does not price, and it is the one worth watching most carefully.